Stewart W C, Kolker A E, Sharpe E D, Day D G, Holmes K T, Leech J N, Johnson M, Cantrell J B
Pharmaceutical Research Corporation, Charleston, South Carolina 29412-2464, USA.
Am J Ophthalmol. 2000 Sep;130(3):274-9. doi: 10.1016/s0002-9394(00)00487-6.
To evaluate long-term risk factors for progression or stability in patients with primary open-angle glaucoma.
We retrospectively included consecutively reviewed patients who had primary open-angle glaucoma for at least 5 years in this multicenter trial. Historical and clinical factors in these patients were evaluated for their association with stability or progression of the glaucoma.
We included 218 patients in this study; of these, 34 progressed over an average length of follow-up of 45.5 +/- 30.0 months, and 184 were stable over an average of 72.8 +/- 18.3 months. The mean intraocular pressure over the follow-up period for the progressed group was 19.5 +/- 3.8 mm Hg and for the stable group 17. 2 +/- 3.1 mm Hg (P =.001). The average standard deviation of individual intraocular pressures was greater in the progressed group (5.1 mm Hg) than the stable group (3.9 mm Hg, P =.012). Baseline characteristics indicating a greater potential to progress were a larger cup-to-disk ratio (P <.001), a greater number of medications (P =.02), older age (P.007), and worse visual acuity (P =.003). However, no difference was observed in pressure levels that prevented progression in these subpopulations compared with the total sample size.
This study suggests that lowering the intraocular pressure is important in the treatment of primary open-angle glaucoma to help prevent long-term progression. Lowering the pressure, however, is not uniformly effective in preventing progression. Additionally, risk factors for progression do not further help identify pressure levels that prevent worsening of glaucoma.
评估原发性开角型青光眼患者病情进展或稳定的长期风险因素。
在这项多中心试验中,我们回顾性纳入了连续接受至少5年原发性开角型青光眼检查的患者。评估这些患者的历史和临床因素与青光眼稳定性或进展的相关性。
本研究纳入218例患者;其中,34例在平均45.5±30.0个月的随访期内病情进展,184例在平均72.8±18.3个月内病情稳定。进展组随访期间的平均眼压为19.5±3.8 mmHg,稳定组为17.2±3.1 mmHg(P = 0.001)。进展组个体眼压的平均标准差(5.1 mmHg)大于稳定组(3.9 mmHg,P = 0.012)。提示进展可能性较大的基线特征包括较大的杯盘比(P < 0.001)、较多的用药数量(P = 0.02)、较高的年龄(P = 0.007)和较差的视力(P = 0.003)。然而,与总样本量相比,在这些亚组中阻止病情进展的眼压水平未观察到差异。
本研究表明,降低眼压在原发性开角型青光眼治疗中对预防长期病情进展很重要。然而,降低眼压在预防进展方面并非始终有效。此外,进展的风险因素无助于进一步确定阻止青光眼病情恶化的眼压水平。